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Alterations in male reproductive function
Changes in the environment and their consequences
for male reproductive function have been of major
concern for the past 20 years [1-3].
Alterations in male reproduction were first
observed in wild animals, in studies reporting the
effects of accidental exposure of estrogenic chemicals
on wildlife in the natural environment. These changes
in male reproductive function vary from very subtle to
permanent alterations, such as feminization or changes
in reproductive behaviour [2,4]. Guillette et al studied
the male reproductive function of alligators in two
lakes in Florida. These two lakes are located very close
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Abstract: There are great concerns about the increasing incidence of abnormalities in male reproductive function. Human
sperm counts have markedly dropped and the rate of testicular cancer has clearly augmented over the past four decades. More-
over, the prevalence rates of cryptorchidism and hypospadias are also probably increasing. It has been hypothesized that all
these adverse trends in male reproduction result from abnormalities in the development of the testis during foetal and neona-
tal life. Furthermore, many recent epidemiological, clinical and experimental data suggest that these male reproductive dis-
orders could be due to the effects of xenobiotics termed endocrine disruptors, which are becoming more and more concen-
trated and prevalent in our environment. Among these endocrine disruptors, we chose to focus this review on the phthalates
for different reasons: 1) they are widespread in the environment; 2) their concentrations in many human biological fluids have
been measured; 3) the experimental data using rodent models suggesting a reprotoxicity are numerous and are the most con-
vincing; 4) their deleterious effects on the in vivo and in vitro development and function of the rat foetal testis have been large-
ly studied; 5) some epidemiological data in humans suggest a reprotoxic effect at environmental concentrations at least dur-
ing neonatal life. However, the direct effects of phthalates on human foetal testis have never been explored. Thus, as we did
for the rat in the 1990s, we recently developed and validated an organ culture system which allows maintenance of the devel-
opment of the different cell types of human foetal testis. In this system, addition of 10-4 M MEHP (mono-2-ethylhexyl phtha-
late), the most produced phthalate, had no effect on basal or LH-stimulated production of testosterone, but it reduced the num-
ber of germ cells by increasing their apoptosis, without modification of their proliferation. This is the first experimental
demonstration that phthalates alter the development of the foetal testis in humans. Using our organotypic culture system, we
and others are currently investigating the effect of MEHP in the mouse and the rat, and it will be interesting to compare the
results between these species to analyse the relevance of toxicological tests based on rodent models.
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to each other geographically, excluding the possibility
of climate-based bias in these studies. They found that
adult male alligators in Apopka Lake, which was pol-
luted with agricultural waste and experienced a major
chemical spill in 1980, had lower testosterone levels
and presented micropenis and disorganized testes
[5,6]. A key part of this story is that no chemicals could
be detected in the water of the apparently contaminat-
ed lake and thus the alligators were being exposed sim-
ply by being at the top of the food chain. Other docu-
mented disruptions or alterations of reproductive
activity and physiology have been correlated with
exposure of contaminants in fish, amphibians, reptiles,
birds, and mammals [4,7,8]. Most of the reported
effects on wildlife have been observed on aquatic
organisms and this is linked to the concentration of
pollutants along the food chain. In humans, there is
increasing evidence that the birth sex ratio is altered in
areas close to industry and exposed to environmental
and industrial chemicals. The findings of the recent
report on the Aamjiwnaang First Nation community in
Canada are striking [9], i.e. the proportion of male live
births in this community has been decreasing continu-
ally from 1990 to 2003, the sex ratio (number of male
births/total number of births) being only 0.3. 
The epidemiologic data have also shown 
an increase in human male reproductive function dis-
orders over the past 50 years, with the suggestion of a
relation with the increase in the amounts of endocrine
disruptors in the environment. Testicular cancer, which
is the most prevalent cancer in young men, has steadi-
ly increased in all countries studied, rising, for exam-
ple, from 3.4 per 10,000 in 1973 to 5.5 per 10,000 in
1997 in North America [10]. Hypospadias and cryp-
torchidism also dramatically increased from 0.2 and
2%, respectively, in 1970 to 0.38 and 3.5%, respec-
tively, in 1991 [10]. Finally, sperm count decline has
been controversial, but large-scale prospective studies
using standardized methodologies have shown 
a decline from 170 to 70 million spermatozoa per mil-
lilitre between 1940 and 1990 in Europe [1,11].
There are grounds for linking these four types of dis-
orders. For example, a comparative study in European
countries showed that the incidence of each of these
four pre-cited abnormalities (sperm count decline, tes-
ticular cancer, hypospadias, and cryptorchidism) was
maximal in Denmark and minimal in Finland [12].
Moreover, a history of cryptorchidism increases the risk
of other three disorders [13], by a factor of 3-17 in the
case of testicular cancer [14]. Similarly, hypospadias
increases the chances of developing testicular cancer
[1], and oligospermia is frequently observed in men
who go on to develop testicular cancer [15,16]. There-
fore, it has been suggested that these four alterations are
symptoms of a single syndrome named the testicular
dysgenesis syndrome (TDS) [16,17].
These abnormalities first arise during foetal
development
The foetal testis is formed by the mixing of a somatic
anlage growing at the surface of the mesonephros and
primordial germ cells that colonize the gonad and are
called gonocytes (reviews in [18], Rouiller-Fabre et al
in this issue). The foetal testis carries out crucial
endocrine and gametogenic functions. Foetal Leydig
cells produce the testosterone and insulin-like factor 
3 (Insl3), which are absolutely necessary for pheno-
typic masculinisation of the embryo [19], (review in
[20]). After birth, gonocytes give rise to the adult stem
spermatogonia and thus correct development of the
germ cell lineage during foetal/embryonic life is essen-
tial for the establishment of the ability of the individ-
ual to produce spermatozoa throughout his life.
It is currently thought that TDS is probably caused
by disturbances in the development of the foetal testis
[16] because the origins of all four characteristics of
TDS can be traced to foetal development.
Hypospadias results from defects in androgen pro-
duction or action during foetal development, while
cryptorchidism results from abnormalities in the pro-
duction and/or activity of Insl3 and/or the androgens
respectively regulating the transabdominal and
transinguinal descent of the testes [19].
The aetiology of testicular cancer remains unclear,
but there is considerable evidence to suggest that it
originates early in development [17] when gonocytes
would normally have differentiated into spermatogo-
nia. Carcinoma in situ (CIS) is a local malignant lesion
that precedes testicular cancer (seminomas and non-
seminomas) [21]. CIS cells closely resemble foetal
germ cells in terms of morphology and immunohisto-
logical markers (c-kit, alkaline phosphatase, etc) [22].
Moreover, CIS has been reported in boys only a few
months old [16].
Finally, sperm counts may have decreased for mul-
tiple reasons as the regulation of spermatogenesis
remains poorly understood, but is known to involve
complex endocrine, intratesticular, and intracellular
regulation processes. The stock of gonocytes is deter-
mined during foetal development and takes part in
determining the number of germ stem cells present in
adulthood, since experimentally induced decreases in
the number of gonocytes during foetal development
lead to decreases in sperm count in adulthood [23,24]
Similar results are obtained if the number of Sertoli
cells is reduced during perinatal life [25]. Thus, adult
sperm production depends partly on foetal seminifer-
ous development.
Numerous clinical, epidemiological and experi-
mental data support the hypothesis that TDS is caused
by endocrine disruptors acting during foetal or neona-
tal life (reviews in [2], [26-28]). Endocrine disruptors
have been quantitatively and qualitatively increasing
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in our environment during the last decades. They orig-
inate from various sources including plants (phytoe-
strogens), agriculture (insecticides, herbicides, fumi-
gants and fungicides) and many chemicals (pharma-
ceutical products, plasticisers, resins, detergents, PCB,
flame retardant, bisphenol A, antimicrobial parabens,
dioxins). In the present study we focused on phtha-
lates.
Environmental exposure to phthalates 
Phthalates (phthalic acid esters) are industrial chemi-
cals that have been used increasingly since 1930. Their
worldwide production grew from 1.8 to 4.3 million
tons between 1970 and 2006. Phthalates are plasticis-
ers that are added to polymers and essentially to PVC
to make them softer and more flexible. They are wide-
ly used in a wide range of soft-PVC products includ-
ing building and construction materials such as
cabling, flooring, wall covering, profiles and roofs.
They are components of medical equipment, hoses,
shower curtains, films and plastic gloves, household
furnishings, toys, car interiors, clothing, food and bev-
erage packaging, pharmaceutical products, etc. Phtha-
lates are also used as solvents for oil-soluble dyes,
insecticides, peroxides, and other organics. They are
added to paints and lacquers, adhesives and sealants,
cosmetics, lubricants, putty, perfumes, deodorants,
sprays. Di(2-ethylhexyl) phthalate (DEHP) is the most
widely used phthalate. One and half million tons of
DEHP are produced every year worldwide (40% in
Europe). Phthalates are not covalently bound to the
product matrix and can leach out over time from these
products. As an example, they are recovered in domes-
tic dust [29]. Dermal exposure via clothes and cosmet-
ics may also occur. Small population groups may be
exposed via medical equipment. So humans are con-
stantly exposed to phthalates through oral, dermal and
inhalation routes [30,31]. In the body, phthalates are
rapidly hydrolyzed by esterases in the gut and other
tissues into monoesters, which are the active mole-
cules [32]. For example, DEHP is metabolized to its
monoester metabolite, mono-(2-ethylhexyl) phthalate
(MEHP), and DBP is converted into mono-butyl
phthalate (MBP).
Whereas many endocrine disruptors are persistent
in the environment and accumulate in fat, the half-life
of phthalates does not exceed 36 h in the body. In
humans, 75% of the DEHP ingested is metabolized and
excreted in urine within 2 days [33]. However, phtha-
lates are so widespread in the environment that humans
are largely exposed. As an example, according to a
study published in 2003, 12% of the German popula-
tion has a daily intake of DEHP that exceeds European
recommendations [34]. In an epidemiologic study,
75% of the 289 human subjects tested were positive for
the presence of four different types of phthalates in
their urine samples [35]. The concentration of phtha-
lates in biological fluids in humans show large individ-
ual variations [36-41]. Values for MEHP are reported
in Table 1. Values for MBP are similar or higher, and
its urinary concentration in pregnant mothers can reach
5.10-6 M. The most recent reports indicate median lev-
els in urine and amniotic fluid of 4.10-7 M for MBP and
8.10-8 M for MEHP [41].
Effects of phthalates on the development of
the rat testis
The first observation of phthalate-induced testicular
injuries was reported using adult rats in 1945 [42]. The
oral administration of DEHP at dietary concentrations of
0.075, 0.75, 1.5 and 5.0% to rats for 90 days resulted in
tubular atrophy and testicular degeneration at the two top
dose levels. Subsequently, Harris et al. found occasional
incidence of tubular atrophy in rats fed 0.5% DEHP in
the diet for periods of 3 or 24 months [43]. Many other
confirmed and explored the testicular effects of phthalate
in experimental animals (review in [44]).
Numerous studies in the rat foetus have shown that
in utero exposure to di (n-butyl) phthalate (DBP) or
DEHP [27,45]). Much attention has been paid to the
analysis of Leydig cell development and function 
[46-52]. In utero exposure to phthalates induces an
abnormal aggregation of the foetal Leydig cells, an
occurrence of intratubular Leydig cells, a reduction of
foetal testosterone production and Leydig cell Insl3
gene expression. This leads to epididymal agenesis,
reduced ano-genital distance, hypospadias and cryp-
torchidism. Furthermore, in utero exposure to phtha-
lates induces subnormal Sertoli cell proliferation [53],
and possibly function [54,55]. Lastly, formation of
multinucleated gonocytes during neonatal life and
impaired spermatogenesis/infertility in adult have
been observed [54,56]. Thus in utero exposure to
phthalate results in a TDS-like syndrome in the male
offspring, except for testicular cancer which is not
induced.
The in vitro approach has also been used for time
and dose analyses of the effects of phthalates on the rat
foetal testis. The main limitation on the toxicological
use of in vitro studies is that the activities and fates of
the cells in vitro must reproduce those existing in vivo.
In mammalian cell culture systems, foetal Leydig cells
dedifferentiate in the absence of specific gonadotropic
stimulation [57-59]. Isolated gonocytes display poor
survival in such systems [60-62]. Organ culture sys-
tems preserving testicular architecture and intercellu-
lar communications appear to us as a relevant method
to maintain the development of the foetal, embryonic
or neonatal testis. Furthermore, one testis can be cul-
tured in the presence of the tested molecule whereas
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the contralateral testis is cultured in its absence. Thus,
an original technique using a filter system was been set
up by Habert's team in 1991 [63] (Fig 1). This tech-
nique reproduces the development of the Leydig, Ser-
toli and germ cells observed in vivo [58,59,64-67].
Thus, this organotypic culture system is an important
tool to study the age-, time- and dose-dependent direct
effects of endocrine disruptors on the development of
the foetal testis [67]. We named this method the rat
foetal testis assay (rFETA) Then, we extended this
method to mouse and human foetal testis [66,68-70]
and named the methods mFETA and hFETA, respec-
tively. Using this system, the effects of MBP and
MEHP were investigated in the rat [71-74]. When
explanted at 13.5 or 14.5 days post partum (dpc), one
group found an MEHP-induced decrease in the num-
ber of gonocytes, and in the production of testosterone
and AMH [74] which were not observed by others
[72,73]. The reasons for these discrepancies are
unclear, but are probably linked to experimental con-
ditions. With foetal testes explanted at 18.5-19.5 dpc,
MEHP or MBP induced reductions in the proliferation
and AMH expression of Sertoli cells and a reduction in
LH-stimulated testosterone production [71,72]. At 
3 days post partum, when proliferation of the gono-
cytes resumes, MEHP induced apoptosis in this cell
type [72]. 
Effects of phthalates on the development of
human foetal testis
Despite the growing body of literature data on phtha-
late reproductive toxicity in animal models, and data
demonstrating extensive human exposure, very few
studies have examined the effects of these chemicals
on human reproductive development. 
Epidemiological studies are highly difficult to
perform because of the numerous factors that can act
on foetal testis development, including hundreds of
endocrine disruptors, alcohol, tobacco, individual
stress. Furthermore, it is important to take into
account the period of exposure. For instance, an asso-
ciation between a low sperm count in adult men with
the treatment of their mother with diethylstilbestrol
(DES) during pregnancy can be demonstrated only if
the data relate to treatment during the first trimester
[75]. Recently, anogenital distance was chosen in
humans as an index of masculinisation and therefore
an index of androgenic activity of the testis. An
inverse correlation has been found between anogeni-
tal distance measured in male infants 2-36 months of
age (mean 12.6 months) and maternal urinary con-
centrations of MBP and 3 other monoester phthalate
metabolites measured at the end of pregnancy [38].
Interestingly, no correlation was observed for MEHP.
In the same way, a concentration-dependent associa-
tion between phthalates in breast milk and levels of
reproductive hormones in boys at 3 months of age
was also reported [39]. However, a recent paper by
Huang et al 2009 reported no association between the
anogenital distance measured in boys at birth and the
concentration of any phthalates in the amniotic fluid
or maternal urine during pregnancy. Taken together,
these epidemiological studies suggest that some
phthalates at environmental concentrations have
antiandrogenic effects during neonatal life. Their
antiandrogenic effects during foetal life are not
demonstrated.
Recently our team reported the first experimental
demonstration of the potential deleterious effect of
phthalates on human testis function or development
[76]. In this study, we used the organ culture system of
human foetal testes that we developed previously cou-
pled with morphologic, functional, and molecular
methods [68-70] to analyse the effects of MEHP on the
development of testicular somatic and germ cells dur-
ing the first trimester of pregnancy (Fig 1). This early
developmental period of the testis has been shown to
be a critical window for the determination of the repro-
ductive tract [77].
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Table 1. Concentrations of MEHP in differents biological fluids in
human
Human foetal testes were recovered during the first
trimester (7-12 weeks) of gestation and cultured for 
3 days with or without MEHP in basal conditions or
stimulated with luteinizing hormone (LH). Whatever
the dose, MEHP treatment had no effect on basal or
LH-stimulated testosterone produced by the human
foetal testis in vitro. MEHP treatment did not affect the
mRNA expression of P450c17, P450scc, or StAR, or
that of Insl3 produced by foetal Leydig cells, which is
known to be involved in testicular descent and the
expression of the steroidogenic enzymes. MEHP
(10-4 M) did not affect proliferation or apoptosis of
Sertoli cells, but it reduced the mRNA expression of
anti-Müllerian hormone. Interestingly, MEHP (10-4 M)
reduced the number of germ cells by increasing their
apoptosis, measured by the detection of caspase-3-pos-
itive germ cells, without modification of their prolifer-
ation.
Conclusions
We review here arguments suggesting that the alter-
ations of the male reproductive functions observed
during the last decades are linked to an increasing
exposure to endocrine disruptors with a focus on 
the phthalates. Our laboratory recently here the first
experimental evidence for the potential of phthalates
to impair the development of foetal testis in the
human species [76]. Interestingly, the main disrup-
tion appears to be of the gametogenic function of the
foetal testis, and no effect was observed on Leydig
cell development and function. In the same way, epi-
demiological studies suggest that the antiandrogenic
effects of environmental phthalates occur in the baby
or the young child and not during foetal life. In rats,
as in humans, phthalates act on foetal/neonatal game-
togenesis, but, unlike in humans, they induce large
antiandrogenic effects. Thus, the relevance of the rat
model for toxicological studies related to phthalates
must be debated.  A recent paper reports that in utero
exposure to phthalates impairs the development of
gametogenesis without alterations of steroidogenesis
of the foetal testis in mouse [78]. Using mouse foetal
testis in culture, we also observed impairment of
gametogenesis and no decrease of steroidogenesis
[79]. Thus it will be important to establish whether
the mouse could be an interesting model for studying
the effects and mechanisms of action of phthalates in
human foetal testicular development.
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Fig. 1. Human foetal testis assay in
humans (hFETA): One testis is cultured
after fragmentation in the presence of the
test compound and the other one from the
same foetus is cultured in the absence of
the test compound and served as control.
MEHP was assayed and micropho-
tographs show the reduction of the num-
ber of gonocytes after 3 days of culture in
the presence of 10-4 M MEHP [76].
Gonocytes are identified as white cells
inside the seminiferous cords, while the
Sertoli cells have been immunostained
for anti-Müllerian hormone.
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